Healius (ASX:HLS) Interest Expense: A$-12 Mil (TTM As of Dec. 2025)

What is Healius Interest Expense?

Healius ASX:HLS +1.39% 53 Interest Expense is A$-12 Mil as of Dec. 2025. GuruFocus rates ASX:HLS with a GF Score™ of 53/100 and a GF Value™ of A$1.01 (Possible Value Trap). The stock has 7 warning signs investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Healius's interest expense for the six months ended in Dec. 2025 was A$ -1 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2025 was A$-12 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Healius's Operating Income for the six months ended in Dec. 2025 was A$ -1 Mil. Healius's Interest Expense for the six months ended in Dec. 2025 was A$ -1 Mil. Healius did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Healius (ASX:HLS) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Healius's Interest Expense for the six months ended in Dec. 2025 was A$-1 Mil. Its Operating Income for the six months ended in Dec. 2025 was A$-1 Mil. And its Long-Term Debt & Capital Lease Obligation for the six months ended in Dec. 2025 was A$761 Mil.

Healius's Interest Coverage for the quarter that ended in Dec. 2025 is calculated as

Healius did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Warning Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Healius Ltd interest coverage is 1.63, which is low.

Healius Interest Expense Historical Data

* Premium members only.

The historical data trend for Healius's Interest Expense can be seen below:

Healius Interest Expense Chart

Healius Annual Data

Trend

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Jun25

Interest Expense

Get a 7-Day Free Trial

-53.60

-15.50

-28.60

-30.00

-26.30

Healius Semi-Annual Data
	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24	Jun25	Dec25
Interest Expense	Get a 7-Day Free Trial															-16.20	-13.80	-15.20	-11.10	-1.20

53GF Score

Healius Ltd ASX:HLS

Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Healius Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-12 Mil.

Frequently Asked Questions Learn more about Interest Expense →

What does a Interest Expense of A$-12 Mil mean?

Healius (ASX:HLS) has a Interest Expense of A$-12 Mil as of Dec. 2025. Interest Expense is the amount a company pays on its long-term debt. View historical data on Healius and its competitors.

Is Healius' Interest Expense too high?

Healius' current Interest Expense is A$-12 Mil. Overall, Healius has a GF Score™ of 53/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.

How does Healius' Interest Expense compare to TMO and DHR?

Healius' Interest Expense of A$-12 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Interest Expense for a Medical Diagnostics & Research company?

A good Interest Expense depends on the Medical Diagnostics & Research industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Interest Expense mean?

A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Healius and its competitors. Healius's current Interest Expense is A$-12 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Healius stock overvalued right now?

Based on GuruFocus' analysis, Healius (ASX:HLS) is currently considered Possible Value Trap. The stock's GF Value™ is A$1.01, compared to a current price of A$0.37 — trading 63.9% below its estimated fair value. The current Interest Expense is A$-12 Mil. Healius' overall GF Score™ is 53/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Interest Expense calculated?

Interest Expense is calculated from a company's financial statements. For Healius (ASX:HLS), the current Interest Expense is A$-12 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Healius (ASX:HLS) Overvalued in 2026?

Based on GuruFocus' analysis, Healius stock appears to be undervalued. The current stock price of A$0.37 is trading 63.9% below its estimated GF Value™ of A$1.01. GuruFocus considers Healius to be Possible Value Trap.

Key valuation signals for ASX:HLS:

Interest Expense: A$-12 Mil
GF Value™: A$1.01 vs. price of A$0.37 (63.9% below fair value)
GF Score™: 53/100 with 7 warning signs

No single metric tells the full story. See the ASX:HLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Healius Business Description

Industry Healthcare Medical Diagnostics & Research

Comparable Companies ASX:MVF ASX:ACL ASX:CTE ASX:IIQ ASX:RHY ASX:MAP ASX:BDX ASX:IME ASX:GSS ASX:IBX TMO DHR SHSE:603259 XSWX:LONN IDXX A WAT NTRA IQV ILMN

Other Exchanges PGZ:Germany

Address 161 Castlereagh Street, Level 22, Sydney, NSW, AUS, 2000

Website https://www.healius.com.au

Healius is Australia's second-largest pathology provider. Pathology revenue is almost entirely earned via the public health Medicare system and makes up the majority of Healius' group revenue. A small portion comes from its clinical testing business, Agilex.

53GF Score

Get the complete analysis for ASX:HLS

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.37

Price

A$1.01

GF Value

View ASX:HLS Analysis

See Interest Expense data for all stocks →